|
|
Vaccine Detail
|
P. falciparum MSP4 with AFCo1 Adjuvant |
| Vaccine Information |
- Vaccine Name: P. falciparum MSP4 with AFCo1 Adjuvant
- Target Pathogen: Plasmodium spp.
- Target Disease: Malaria
- Vaccine Ontology ID: VO_0004243
- Type: Subunit vaccine
- Status: Research
- MSP4
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Adjuvant:
- Immunization Route: Not specified
|
| Host Response |
|
Mouse Response
- Host Strain: BALB/c
- Vaccination Protocol: MIce were immunized at 14-day intervals with three doses of 10 μg MSPs (Bracho et al., 2009).
- Immune Response: AFCo1 significantly enhanced the IgG and T-cell response against MSP4, with a potency equivalent to CFA, with the response being characterized by both IgG1 and IgG2a isotypes, increased interferon gamma production and a strong DTH response, consistent with the ability of AFCo1 to induce Th1-like immune responses (Bracho et al., 2009).
|
| References |
Bracho et al., 2009: Bracho G, Zayas C, Wang L, Coppel R, Pérez O, Petrovsky N. AFCo1, a meningococcal B-derived cochleate adjuvant, strongly enhances antibody and T-cell immunity against Plasmodium falciparum merozoite surface protein 4 and 5. Malaria journal. 2009; 8; 35. [PubMed: 19250541].
|
|
